Sepin-1
Based on 2 publication(s) in Google Scholar
Sepin-1 is a potent separase inhibitor with an IC50 value of 14.8 µM. Sepin-1 inhibits cell proliferation, migration and wound healing. Sepin-1 decreases the expression of FoxM1 protein and mRNA level. Sepin-1 shows anti-tumor activity.
For research use only. We do not sell to patients.
- Purity: 99.29%
- CAS No.: 163126-81-6
- Formula: C9H9N3O4
- Molecular Weight:223.19
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Sepin-1
More
Biological Activity
IC50: 14.8 µM (separase)[2]
Sepin-1 (0, 20, 40 µM; 24 h) inhibits cell migration and wound healing, and causes DNA damage[1].
Sepin-1 (0, 10, 20, 40 µM; 24 h) decreases the expression of FoxM1 protein and mRNA level in a dose-dependent manner[1].
Sepin-1 (0, 10, 20, 40 µM; 24 h) inhibits the expression of Plk1, Cdk1, pericentrin, Aurora, and Lamin B1 protein levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BT-474, MCF7, MDA-MB-231, MDA-MB-468 cells
-
Concentration:0-64 µM
-
Incubation Time:3 days
-
Result:Inhibited cell growth with EC50s of 18.03, 17.66, 27.33, 27.92 µM for BT-474, MCF7, MDA-MB-231, MDA-MB-468 cells, respectively.
-
Cell Line:BT-474, MCF7, MDA-MB-231, MDA-MB-468 cells
-
Concentration:0, 10, 20, 40 µM
-
Incubation Time:24 h
-
Result:Decreased the expression of FoxM1 protein in a dose-dependent manner, and decreased teh expression of A-Raf, B-Raf, and C-Raf.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID beige mice (MCF7 xenografts)[2]
-
Dosage:10 mg/kg
-
Administration:I.v.; daily for 5 days a week for 3 weeks
-
Result:Inhibited tumor growth.
Chemical Information
-
CAS No. 163126-81-6
-
Appearance Solid
-
Molecular Weight 223.19
-
Formula C9H9N3O4
-
Color Brown to reddish brown
-
SMILES
[O-][N+]1=C2C(C=C(C=C2)[N+]([O-])=O)=[N+](C1(C)C)[O-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
MedComm (2020)
Separase Inhibition Enhances Gefitinib Sensitivity of Lung Cancer via PTBP1/TAK1/RIPK1-Mediated PANoptosis. [Abstract]2025 Oct 20;6(11):e70432. PMID: 41122447 -
J Cell Sci
14-3-3ε inhibits premature centriole disengagement by inhibiting the activity of Plk1 and separase. [Abstract]2025 Jul 15;138(14):jcs263808. PMID: 40576425
Solvent & Solubility
DMSO : 100 mg/mL (448.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang N, et al. Separase Inhibitor Sepin-1 Inhibits Foxm1 Expression and Breast Cancer Cell Growth. J Cancer Sci Ther. 2018;10(3):517. [Content Brief]
[2]. Zhang N, et al. Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy. J Biomol Screen. 2014 Jul;19(6):878-89. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.4805 mL | 22.4024 mL | 44.8049 mL | 112.0122 mL |
| 5 mM | 0.8961 mL | 4.4805 mL | 8.9610 mL | 22.4024 mL | |
| 10 mM | 0.4480 mL | 2.2402 mL | 4.4805 mL | 11.2012 mL | |
| 15 mM | 0.2987 mL | 1.4935 mL | 2.9870 mL | 7.4675 mL | |
| 20 mM | 0.2240 mL | 1.1201 mL | 2.2402 mL | 5.6006 mL | |
| 25 mM | 0.1792 mL | 0.8961 mL | 1.7922 mL | 4.4805 mL | |
| 30 mM | 0.1493 mL | 0.7467 mL | 1.4935 mL | 3.7337 mL | |
| 40 mM | 0.1120 mL | 0.5601 mL | 1.1201 mL | 2.8003 mL | |
| 50 mM | 0.0896 mL | 0.4480 mL | 0.8961 mL | 2.2402 mL | |
| 60 mM | 0.0747 mL | 0.3734 mL | 0.7467 mL | 1.8669 mL | |
| 80 mM | 0.0560 mL | 0.2800 mL | 0.5601 mL | 1.4002 mL | |
| 100 mM | 0.0448 mL | 0.2240 mL | 0.4480 mL | 1.1201 mL |